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Cyclooxygenase-2 (COX-2) is overexpressed in several epithelial tumours, including breast cancer. Cyclooxygenase-2-positive
tumours tend to be larger, higher grade, node-positive and HER-2/neu-positive. High COX-2 expression is associated with poor
prognosis. Cyclooxygenase-2 inhibition reduces the incidence of tumours in animal models, inhibits the development of invasive
cancer in colorectal cancer and reduces the frequency of polyps in familial adenomatous polyposis (FAP). These effects may be as a
result of increased apoptosis, reduced angiogenesis and/or proliferation. Studies of COX-2 inhibitors in breast cancer are underway
both alone and in combination with other agents. There is evidence to suggest that combining COX-2 inhibitors with aromatase
inhibitors, growth factor receptor blockers, or chemo- or radiotherapy may be particularly effective. Preliminary results from
combination therapy with celecoxib and exemestane in postmenopausal women with advanced breast cancer showed that the
combination increased the time to recurrence. Up to 80% of ductal carcinomas in situ (DCISs) express COX-2, therefore COX-2
inhibition may be of particular use in this situation. Cyclooxygenase-2 expression correlates strongly with expression of HER-2/neu.
As aromatase inhibitors appear particularly effective in patients with HER-2/neu-positive tumours, the combination of aromatase
inhibitors and COX-2 inhibitors may be particularly useful in both DCIS and invasive cancer.
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Preclinical and clinical evidence shows that prostaglandins play
an important role in the growth and development of cancer.
Prostaglandin endoperoxide synthase (also called cyclooxygenase;
COX) is the rate-limiting enzyme involved in the oxidative
transformation of arachidonic acid into prostaglandin H2, which
represents the precursor of several bioactive molecules, including
prostaglandin E2 (PGE2), prostacyclin and thromboxane. There are
at least two isoforms of the COX enzyme: cyclooxygenase-1 (COX-1)
and cyclooxygenase-2 (COX-2) (Hla et al, 1999). Both isoforms are
found in most human tissues, but while COX-1 is constitutively
expressed at low levels (O’Neill and Ford-Hutchinson, 1993), COX-2
expression is an immediate-early response gene that is inducible in
response to a variety of stimuli. Cyclooxygenase-2 is induced by a
number of promoters (Herschman, 1996), including stimulation
of the epidermal growth factor receptor HER-2/neu (also called
c-erbB2) pathway through RAS and the NFkB and NFIL6 inflamma-
tion pathways. Overexpression of COX-2 is detected in several
epithelial tumours including those of the colon, lung, breast,
prostate, skin, oesophagus, pancreas and bladder. New blood vessels
surrounding tumours have COX-2 within them (Sano et al, 1995;
Chan et al, 1999; Tucker et al, 1999) and, therefore, COX-2
inhibition targets not only the epithelial cells of tumours but also the
endothelial cells. In neoplasia, COX-2 promotes tumour angio-
genesis (Chang et al, 2004) and inhibits apoptosis (Hsu et al, 2000).
Overexpression of COX-2 in the breast tissue of transgenic mice
is associated with increased development of breast tumours, but
only after multiple pregnancies (Liu et al, 2001). Breast tissues that
express COX-2 in these transgenic mice have reduced levels of
apoptosis compared with normal tissue (Liu et al, 2001). In
humans, COX-2 is raised in both ductal carcinoma in situ (DCIS,
Half et al, 2002) and invasive breast cancer (Spizzo et al, 2003;
Boland et al, 2004; Figure 1) and appears to be associated with
higher proliferation, lower apoptosis and increased new blood
vessel formation (Kirkpatrick et al, 2001; Boland et al, 2004).
Indeed, a large study of 1576 patients with invasive breast cancer
demonstrated that COX-2 was expressed at high levels in over 50%
of patients and these patients had a significantly worse disease-free
survival compared with patients whose tumours expressed low-
levels of, or absent, COX-2 (Ristimaki et al, 2002). Studies with
celecoxib, a selective COX-2 inhibitor, in an HER2/neu-induced
breast cancer model in transgenic mice have revealed that
celecoxib reduced the incidence of mammary tumours and
lowered mammary PGE2 levels by 50% (Howe et al, 2002; Lanza-
Jacoby et al, 2003).
In colorectal cancer and familial adenomatous polyposis (FAP),
COX-2 inhibition has been shown to inhibit the development of
invasive cancer and reduce the frequency of polyp formation
(Giardiello et al, 1993; Steinbach et al, 2000; Phillips et al, 2002;
Asano and McLeod, 2004). In a pivotal study, 6 months of
treatment with celecoxib, 400mg b.i.d. (twice the licensed
antiarthritis dose) significantly prevented polyp formation com-
pared with placebo (Phillips et al, 2002). Studies have also
suggested that combinations of COX-2 inhibitors with an
epidermal growth factor receptor (EGFR) inhibitor have synergis-
tic benefits in animal models of FAP (min mouse) (Torrance et al,
2000). Other studies have shown a potential benefit of COX-2
inhibitors in non-small-cell lung cancer (Altorki et al, 2003).
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(Masferrer et al,2 0 0 0 ;F uet al 2004) has clearly shown that COX-2
inhibition with celecoxib prevents the growth of lung, colon and
breast human tumour xenografts in nude mice (Figure 2). The
growth of both MDA-MB231 cells, an oestrogen receptor (ER)-
negative, EGFR-positive RAS transformed breast cancer cell line and
HER18 cells, an ER-positive, HER-2/neu transfected MCF-7 breast
cancer cell line, were both markedly inhibited by celecoxib in a
xenograft model (Figure 2C; Barnes et al, 2003). These data suggest
that celecoxib may help to prevent ER-negative cancers and be of
value in HER-2/neu-positive breast cancer. Studies of COX-2
inhibitors in breast cancer are underway as adjuvant therapy.
MECHANISMS OF ACTION OF COX-2 INHIBITORS
There are three potential anticancer mechanisms for COX-2
inhibition, it may
  inhibit proliferation in epithelial cells,
  increase apoptosis,
  reduce angiogenesis.
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Figure 1 COX-2 is strongly expressed in the cell cytoplasm in (A)
ductal carcinoma in situ and (B) invasive breast cancer. For comparison, (C)
shows COX-2 as negatively expressed in a ductal carcinoma in situ with
little staining.
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Figure 2 Celecoxib, a COX-2 inhibitor, slows growth of cancer cell lines
derived from (A) lung, (B) colon and (C) breast when xenografted into
mice (Masferrer et al, 2000; Barnes et al, 2003). (C) Median tumour
growth, bars¼interquartile range. Figures (A) and (B) reproduced with
permission from Masferrer et al (2000).
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Data from studies that have looked at COX-2 expression and
proliferation markers, such as Ki67, have shown a strong
correlation between the presence of COX-2 and increased
proliferation (Ferrandina et al, 2003; Boland et al, 2004), but as
yet no data have been published to show that inhibition of COX-2
leads to a lower proliferative rate in tumours in vivo.
Apoptosis
Several lines of study have indicated that COX-2 inhibition may
increase apoptosis. In a study investigating the effect of celecoxib
on prostate cancer cell lines, AKT phosphorylation was signifi-
cantly inhibited by celecoxib leading to increased caspase-3
activation and apoptosis (Hsu et al, 2000). Celecoxib has also
recently been shown to decrease the activation of the transcription
factor NFkB in lung cancer cell lines (Shishodia et al, 2004);
celecoxib was found to interfere with the tumour necrosis factor-
alpha (TNF-a) induced interaction of AKT with IKK (the protein
kinase required for NFkB activation). NFkB regulates a wide
spectrum of genes including those involved in the immune
response, cell proliferation and apoptosis.
Since HER-2/neu regulates AKT phosphorylation down-
stream (Nicholson et al, 2003), it is certainly conceivable that
inhibiting COX-2 may affect this pathway upstream leading
to increased apoptosis. As previously mentioned, in COX-2
transgenic mice, mouse mammary tissue had significantly less
apoptosis than normal tissue and had a reduced expression of
Bcl2-XL and BAX (Liu et al, 2001), which are both proapoptotic
proteins. Also, it may be that COX-2 affects the mitochondrial
pathway (an intrinsic pathway that induces apoptosis in the
normal breast).
Angiogenesis
Celecoxib inhibition of COX-2 is one of the most potent
antiangiogenic mechanisms currently available to the clinician.
Multiple publications from Dubois and co-workers have indicated
that COX-2 inhibition leads to a reduced secretion of vascular
endothelial growth factor (VEGF) and in vitro reduced endothelial
tube formation in matrigel (Tsujii et al, 1998; Sawaoka et al, 1999;
Woods et al, 2003). Celecoxib has been shown to inhibit basic
fibroblast growth factor-induced angiogenesis in vivo using a rat
corneal angiogenesis model (Masferrer et al, 2000). Furthermore,
lung cancer xenografts showed decreased vascularity when
implanted into COX-2 null mice (Williams et al, 2000). Chang
et al have shown that COX-2 regulates angiogenesis in normal
mammary tissue via PgE2 production; therefore, inhibition of
angiogenesis by COX-2 inhibitors has the potential for chemo-
prevention of breast cancer.
In invasive breast cancer, COX-2 expression has been shown
to correlate with the levels of angiogenesis (measured by
CD-31 staining) in tumours (Davies et al, 2003). In addition,
preliminary results, from a randomised trial using celecoxib given
for 2 weeks before surgery compared with no treatment, have
shown a significant fall in serum VEGF levels after 14 days of
treatment, indicating that celecoxib may be useful in preventing
angiogenesis and lymphovascular spread at around the time of
surgery (O-Donoghue et al, 2004). Therefore, there is increasing
interest in examining COX-2 inhibitors in breast cancer, alone or
in combination with other agents, to determine the overall
effect on prevention, recurrence after early breast cancer treatment
and induction of endocrine response in advanced disease. The
antiangiogenic and proapoptotic effects seen indicate that the
drug may potentially be effective in both ER-positive and -negative
tumours.
INTEGRATING COX-2 INHIBITION INTO BREAST
CANCER TREATMENT
With preclinical studies demonstrating an effect of COX-2
inhibition on tumour growth in animal models and COX-2 being
involved in breast carcinogenesis, COX-2 inhibition is being
considered for inclusion into breast cancer therapy. It is likely that
COX-2 inhibitors will be used as combination therapy with
hormonal agents, such as an aromatase inhibitor to decrease
aromatisation and angiogenesis, or with growth factor receptor
blockers, such as trastuzumab (Herceptin
s), to synergise blockade
of the HER-2/neu RAS pathway inhibition. Also, COX-2 inhibition
has been shown in animal models to make tumours significantly
more chemo- and radio-sensitive. Therefore, several combinations
are being explored in current clinical trials.
Rofecoxib was recently withdrawn from the market due to an
increased risk of cardiovascular events found in both the Vioxx
Gastrointestinal Outcomes Research (VIGOR) study and the
recent Adenomatous Polyp Prevention on Vioxx (APPROVe)
trial. The cardiovascular safety of celecoxib is currently being
examined following results from one trial, the Adenoma Preven-
tion with Celecoxib (APC) trial, which found patients taking
400 and 800mgday
 1 of celecoxib had a 2.5- to 3.4-fold
increased risk of major fatal or nonfatal cardiovascular events
vs placebo (average duration of treatment 33 months). The
use of celecoxib in this trial has now been suspended. Data
suggest that any cardiovascular concerns may be related to
long-term use (412 months) of celecoxib. By contrast, no
increased risk has been seen for celecoxib 400mgday
 1 vs placebo
in two separate long-term studies, the Prevention of Spontaneous
Adenomatopus Polyps (PreSAP) trial and the Alzheimer’s
Disease Anti-inflammatory Prevention Trial (ADAPT). Addition-
ally, no cardiovascular concerns have been noted in over 40000
celecoxib-treated patients. Several trials investigating celecoxib in
preinvasive, invasive and metastatic breast cancer are ongoing as
shown in Table 1.
It is recommended that patients with a history of ischaemic
heart disease or cardiovascular disease should not receive a COX-2
inhibitor.
Combining COX-2 inhibitors with aromatase inhibitors
Brueggemeier et al (1999, 2001) looked at the levels of aromatase
(cyp19) and cox-2 gene expression in breast tissue using the
semiquantative, reverse transcriptase polymerase chain reaction
(RT-PCR) technique. High levels of cox-2 mRNA expression led to
increased levels of PGE2, which in turn increased cyp19 expression.
This was achieved through increased intracellular cAMP levels and
activation of the cyp19 promoter 2, resulting in increased
aromatase activity (Richards et al, 2002). Zhao et al (1996) have
shown that the level of aromatase activity is markedly increased in
the presence of PGE2. Other workers have indicated that the PGE2
and cytokines such as interleukin-6 or TNF-a regulate aromatase
activity in tumour cells (Michael et al, 1997; Brueggemeier et al,
2001). Therefore, inhibition of PGE2 by COX-2 inhibitors may
inhibit aromatase activity and, when combined with aromatase
inhibitors, reduce tumour recurrence by inhibiting a common
target: aromatase.
Pesenti et al (2001) provided preclinical data from a rodent
model in which celecoxib combined with exemestane significantly
inhibited the growth of mammary tumours compared with vehicle
or celecoxib alone and slowed the growth of established tumours at
5 weeks (Figure 3). Results of a small, randomised, phase II study
in postmenopausal women (n¼111) with advanced breast cancer
treated with exemestane, 25mg q.d. and celecoxib, 400mg p.o.
b.i.d. indicated a longer time to breast cancer recurrence with no
additional side effects from the use of celecoxib and exemestane
(Dirix et al, 2003). Pharmacogenomic studies are planned to
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celecoxib.
Other potential COX-2 combinations
Trastuzumab Several studies have shown that up to 80% of
DCISs express COX-2 and that its expression correlates strongly
with expression of HER-2/neu in the same tumours (Half et al,
2002; Tan et al, 2004). Cyclooxygenase-2 expression has been
associated with higher grade ER-negative, HER-2/neu-positive
tumours and COX-2-positive tumours have been linked with a
significantly worse overall survival (Ristimaki et al, 2002).
Therefore, in the group of women with HER-2/neu-positive
tumours, it may be beneficial to use COX-2 inhibition in
combination with an agent such as trastuzumab (Herceptin
s),
which blocks the extracellular domain of the HER-2/neu receptor
and inhibits RAS and MAPkinase signalling. A phase II,
randomised trial of trastuzumab, with or without celecoxib, in a
series of 12 patients with metastatic breast cancer who had
previously progressed after trastuzumab-based treatments, found
that there was no treatment effect, although the drug combination
was well tolerated (Dang et al, 2004). This study consisted only of
patients who had been pretreated with trastuzumab. The effect on
treatment-naı ¨ve patients is still unknown and being investigated in
an ongoing trial.
Chemotherapy Blocking PGE2 production by inhibiting COX-2
has recently been shown to have effects upstream of the HER-2/
neu pathway resulting in decreased HER-2/neu protein levels and
increased sensitivity of cancer cells to chemotherapeutic treatment
(Benoit et al, 2004). Coadministration of celecoxib and cyclophos-
phamide was significantly more effective in preventing growth of
Lewis lung cancer tumours than either drug alone (Koki et al,
1999) and studies of combination of several chemotherapy agents
with celecoxib have indicated that celecoxib lowers the threshold
of sensitivity to chemotherapy (Altorki et al, 2003; Nakata et al,
2004). In Europe, a phase III, multicentre, double-blind, rando-
mised trial of celecoxib vs placebo following chemotherapy
(REACT Trial; Current Controlled Trials) has been initiated in
primary breast cancer patients, although the protocol for this
study is currently under review. Primary breast cancer patients
who have completed surgery, neoadjuvant chemotherapy and
radiotherapy are randomised to receive celecoxib, 400mg twice
a day for 2 years, or placebo, with exemestane given to all
ER-positive patients for 5 years. This study aims to determine
whether the addition of celecoxib improves overall survival in
patients at high risk of recurrence.
COX-2 and aromatase inhibition in DCIS
The high expression of HER-2/neu and COX-2 in DCIS (particu-
larly high grade) combined with the clear correlation between
proliferation and COX-2 expression in DCIS (Boland et al, 2004)
has stimulated interest in the use of COX-2 inhibitors to prevent
recurrent DCIS in ER-positive and -negative disease. Clear
evidence from both the ATAC (Baum et al, 2003) study and
the Letrozole/Tamoxifen Neoadjuvant Trial has suggested that
aromatase inhibition is the treatment of choice in HER-2/neu-
positive, ER-positive tumours (Ellis et al, 2001). In a 3-month
neoadjuvant study, letrozole was 28 times more likely than
tamoxifen to induce response in HER-2/neu-positive, ER-positive,
invasive breast cancer, with 88% of patients responding to
the aromatase inhibitor and 21% to tamoxifen. By contrast, in
Table 1 Overview of current clinical trials of COX-2 inhibitors in the treatment of breast cancer
Trial Principal investigator (Ref)
UK multicentre phase III trial of exemestane and COX-2 inhibition in ER-positive DCIS Bundred (National Cancer Research Network, 2005)
Neoadjuvant celecoxib plus fluorouracil, epirubicin and cyclophosphamide for the treatment of locally advanced
breast cancer
Chow et al (2003)
KUMC-HSC-8919-02: phase II chemoprevention study of celecoxib in premenopausal women at high risk of
ER-negative breast cancer
Fabian (National Cancer Institute, 2005a)
Italian breast cancer trial of celecoxib in combination with weekly taxotere and capecitabine as first-line therapy
in advanced breast cancer
Gasparini et al (2003)
ICCG: pilot study, DNA microarray analysis of human breast cancer before and after treatment with COX-2
inhibitors: search for biomarkers
Hupperets, Wagstaff (Gasparini et al, 2003)
Royal Infirmary phase III, randomised, placebo-controlled trial of celecoxib in patients with metastatic breast
cancer
McMillan (Gasparini et al, 2003)
Phase 1 trial of vinorelbine and celecoxib in treating women with relapsed or metastatic breast cancer Overmoyer (Clinical Trials.gov)
MSKCC-03027: phase I, randomised study of celecoxib in postmenopausal women with invasive breast cancer
undergoing surgery, to look for suppression of aromatase activity and biomarkers of effect
Port, Hudis (National Cancer Institute, 2005b)
CALGB-40105: phase II, randomised study of celecoxib in women with metastatic or recurrent breast cancer,
comparing low dose to high-dose treatment. Further recruitment of patients to celecoxib is under discussion.
Shapiro (National Cancer Institute, 2005c)
NCI-04-C-0044: phase II study of exemestane alone or in combination with celecoxib in postmenopausal
women at high risk for invasive breast cancer
Zujewski (National Cancer Institute, 2005d)
DCIS¼ductal carcinoma in situ;E R¼oestrogen receptor.
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Figure 3 Combined celecoxib (CXB) and exemestane (EXE), reduces
mammary tumour growth in a rodent model more effectively than either
therapy alone (Pesenti et al, 2001).
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and 42% to tamoxifen (Ellis et al, 2001). The recently published
results of the ATAC trial comparing anastrozole with tamoxifen
demonstrated a reduction in recurrence of over 8% in ER-positive,
PR-negative patients (predominantly HER-2/neu-positive group)
compared with a 4% difference in the ER-positive, PR-positive
group (Baum et al, 2003; Dowsett et al, 2003). This would suggest
that aromatase inhibition would be more beneficial in those
patients who express HER-2/neu. The mechanism for this is not
fully clear; however, tamoxifen translocates the ER complex to the
nucleus, opening up DNA and allowing some agonist activity with
coactivators, whereas aromatase inhibition does not (Ellis et al,
2001). Therefore, the HER-2/neu pathway cannot affect the
coactivators or corepressors that have been induced by transloca-
ting the ER to the nucleus. There is evidence that expression of AIB
(amplified in breast cancer 1), a nuclear coactivator complex, is
upregulated in HER-2/neu-positive tumours and is associated with
endocrine resistance (Osborne et al, 2002). Preventing transloca-
tion of the ER to the nucleus lowers oestrogen levels in the breast
and tumour tissue and lowers AIB levels, therefore decreasing
endocrine resistance (Shou et al, 2002).
With 70% of DCISs expressing HER-2/neu (Tan et al, 2002), it is
possible that combining COX-2 inhibition with an aromatase
inhibitor in DCIS patients will reduce recurrence in both the
ipsilateral and contralateral breast. Early, placebo-controlled studies
in DCIS are assessing the effects of administering celecoxib for 14
days on proliferation, apoptosis and angiogenesis in the presurgical
setting. Studies in the USA are looking at the effect of celecoxib on
ER-negative DCIS in this setting and in the UK on ER-positive DCIS.
In addition, trials have been proposed using adjuvant celecoxib in
ER-negative DCIS to determine whether it prevents recurrence after
wide local excision. Given the lack of chemopreventive agents that
can be used to prevent ER-negative breast cancer or used as adjuvant
therapy in ER-negative breast cancer, there is a potential primary
role for celecoxib in this setting.
CONCLUSIONS
Animal studies and early patient trials have shown encouraging
results for the use of COX-2 inhibition alone and/or with other
therapeutic agents in breast cancer and other oncology settings,
including colorectal cancer and non-small-cell lung cancer. In
particular, combining an aromatase inhibitor with a COX-2
inhibitor has been hypothesised to reduce overall disease
recurrence by inhibiting a common target, aromatase. A number
of trials are ongoing to test this hypothesis further and results are
awaited with interest.
REFERENCES
Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara
CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW, Dannenberg AJ
(2003) Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the
response to preoperative paclitaxel and carboplatin in early-stage non-
small-cell lung cancer. J Clin Oncol 21: 2645–2650
Asano TK, McLeod RS (2004) Nonsteroidal anti-inflammatory drugs and
aspirin for the prevention of colorectal adenomas and cancer: a
systematic review. Dis Colon Rectum 47: 665–673
Barnes NLP, Warnberg F, White D, Anderson E, Bundred NJ (2003)
Cyclooxygenase-2 inhibition and tumour growth: celecoxib increases
apoptosis in HER2 positive cell lines. Breast Cancer Res Treat 82(suppl 1)
(Abstract 667)
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T,
The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’
Group (2003) Anastrozole alone or in combination with tamoxifen vs
tamoxifen alone for adjuvant treatment of postmenopausal women with
early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen
Alone or in Combination) trial efficacy and safety update analyses.
Cancer 98: 1802–1810
Benoit V, Relic B, Leval Xd X, Chariot A, Merville MP, Bours V (2004)
Regulation of HER-2 oncogene expression by cyclooxygenase-2 and
prostaglandin E2. Oncogene 23: 1631–1635
Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2
expression is associated with an aggressive phenotype in ductal
carcinoma in situ. Br J Cancer 90: 423–429
Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson
FM (1999) Correlation of aromatase and cyclooxygenase gene expression
in human breast cancer specimens. Cancer Lett 140: 27–35
Brueggemeier RW, Richards JA, Joomprabutra S, Bhat AS, Whetstone JL
(2001) Molecular pharmacology of aromatase and its regulation by
endogenous and exogenous agents. J Steroid Biochem Mol Biol 79: 75–84
Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D,
Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ (1999)
Cyclooxygenase-2 expression is up-regulated in squamous cell carcino-
ma of the head and neck. Cancer Res 59: 991–994
Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane
TF, Hla T (2004) Role of prostaglandin E2-dependent angiogenic switch
in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad
Sci USA 101: 591–596
Chow LW, Toi M, Takebayashi Y (2003) Neoadjuvant celecoxib and
5-fluorouracil/epirubicin/cyclophosphamide (FEC) for the treatment
of locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 22:
82 (Abstract 327)
Clinical Trials.gov Vinorelbine and celecoxib in treating women with
relapsed or metastatic breast cancer, http://www.clinicaltrials.gov/ct/
show/NCT00075673, last viewed February 2005
Current Controlled Trials A phase III multicentre double blind randomised
trial of celecoxib vs placebo following chemotherapy in primary breast
cancer patients, http://controlled-trials.com/isrctn/trial/|/0/48254013.
html, last viewed February 2005
Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM,
Seidman AD, D’Andrea GM, Theodoulou M, Panageas KS, Norton L,
Hudis CA (2004) Phase II study of celecoxib and trastuzumab in
metastatic breast cancer patients who have progressed after prior
trastuzumab-based treatments. Clin Cancer Res 10: 4062–4067
Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M (2003)
Correlation between cyclooxygenase-2 expression and angiogenesis in
human breast cancer. Clin Cancer Res 9: 2651–2656
Dirix LY, Ignacio J, Nag S (2003) Final results from an open-label,
multicenter, controlled study of exemestane +/  celecoxib in post-
menopausal women with advanced breast cancer (ABC) progressed on
tamoxifen (T). Proc Am Soc Clin Oncol 22: 20 (Abstract 77)
Dowsett M, on behalf of the ATAC Trialists Group (2003) Analysis of time
to recurrence in the ATAC (arimidex, tamoxifen, alone or in combina-
tion) trial according to estrogen and progesterone receptor status. Breast
Cancer Res Treat 82(Suppl 1): 6 (Abstract 4)
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller
WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001)
Letrozole is more effective neoadjuvant therapy than tamoxifen for ErbB-
1- and ErbB-2-positive, estrogen receptor-positive primary breast cancer:
evidence from a phase III randomized trial. J Clin Oncol 19: 3808–3816
Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, Testa
AC, Werner U, Navarra P, Tringali G, Battaglia A, Scambia G (2003)
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apopto-
sis-related marker, and microvessel density in human cervical cancer: a
pilot study. Clin Cancer Res 9: 4324–4331
Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y (2004) Anti-cancer effects of
COX-2 inhibitors and their correlation with angiogenesis and invasion in
gastric cancer. World J Gastroenterol 10: 1971–1974
Gasparini G, Longo R, Sarmiento R, Morabito A (2003) Inhibitors of
cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4:
605–615
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P,
Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and
rectal adenomas with sulindac in familial adenomatous polyposis. N Engl
J Med 328: 1313–1316
Potential of COX-2–aromatase inhibitor combinations
NJ Bundred and NLP Barnes
S14
British Journal of Cancer (2005) 93(Suppl 1), S10–S15 & 2005 Cancer Research UKHalf E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002)
Cyclooxygenase expression in human breast cancers and adjacent ductal
carcinoma in situ. Cancer Res 62: 1676–1681
Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta
1299: 125–140
Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC (1999)
Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 31:
551–557
Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler
HT, Muller WJ, Du B, Brown AM, Dannenberg AJ (2002) Celecoxib, a
selective cyclooxygenase 2 inhibitor, protects against human epidermal
growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res
62: 5405–5407
Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The
cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt
activation in human prostate cancer cells independently of Bcl-2. J Biol
Chem 275: 11397–11403
Kirkpatrick K, Ogunkolade W, Elkak AE (2001) The association between
cyclo-oxygenase-2 expression and cell proliferation and angiogenesis in
human breast cancer. Breast Cancer Res 3(Suppl 1): A37
Koki AT, Leahy KM, Masferrer JL (1999) Potential utility of COX-2
inhibitors in chemoprevention and chemotherapy. Expert Opin Invest
Drugs 8: 1623–1638
Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL,
Zweifel BS, Sembhi H, Russo IH (2003) The cyclooxygenase-2 inhibitor,
celecoxib, prevents the development of mammary tumors in HER-2/neu
mice. Cancer Epidemiol Biomarkers Prev 12: 1486–1491
Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C,
Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to
induce tumorigenesis in transgenic mice. JB i o lC h e m276: 18563–18569
Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM,
Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic
and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:
1306–1311
Michael MD, Michael LF, Simpson ER (1997) A CRE-like sequence that
binds CREB and contributes to cAMP-dependent regulation of the
proximal promoter of the human aromatase P450 (CYP19) gene. Mol Cell
Endocrinol 134: 147–156
Nakata E, Mason KA, Hunter N (2004) Potentiation of tumor response to
radiation or chemoradiation by selective cyclooxygenase-2 enzyme
inhibitors. Int J Radiat Oncol Biol Phys 58: 369–375
National Cancer Institute (2005a) Phase II chemoprevention study of
celecoxib in premenopausal women at high risk for estrogen receptor-
negative breast cancer, http://cancer.gov/search/ViewClinicalTrials.aspx?
cdrid¼271935&version¼HealthProfessional&protocolsearchid¼1103726,
last viewed February 2005
National Cancer Institute (2005b) Phase I randomized study of celecoxib
in postmenopausal women with invasive breast cancer undergoing
surgery, http://cancer.gov/clinicaltrials/MSKCC-03027#AlternateTitle_
CDR0000329919, last viewed February 2005
National Cancer Institute (2005c) Phase II randomized study of celecoxib in
women with metastatic or recurrent breast cancer, http://cancer.gov/search/
ViewClinicalTrials.aspx?cdrid¼256905&version¼HealthProfessional&
protocolsearchid¼1103726, last viewed February 2005
National Cancer Institute (2005d) Phase II study of exemestane alone or in
combination with celecoxib in postmenopausal women at high risk for
invasive breast cancer, http://cancer.gov/search/ViewClinicalTrials.aspx?
cdrid¼367245&version¼HealthProfessional&protocolsearchid¼1103726,
last viewed February 2005
National Cancer Research Network (2005) ERISAC Effects of exemestane
and COX-2 inhibition on oestrogen receptor positive ductal carcinoma in
situ, http://www.ncrn.org.uk/portfolio/data.asp?ID¼1367, last viewed
February 2005
Nicholson KM, Streuli CH, Anderson NG (2003) Autocrine signalling through
erbB receptors promotes constitutive activation of protein kinase B/Akt in
breast cancer cell lines. Breast Cancer Res Treat 81: 117–128
O-Donoghue GT, Roche-Nagloe G, Connolly EM, Harmey J, Bouchier-
Hayes D (2004) Selective COX-2 inhibition attenuates the perioperative
increase of the tumour enhancing proangiogenesis cytokine VEGF in
human breast cancer. Br J Surg 91(Suppl 1): 43
O’Neill GP, Ford-Hutchinson AW (1993) Expression of mRNA for
cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett
330: 156–160
Osborne CK, Bardou V-J, Hilsenbeck SG, Fuqua SA, Hopp T, Chamness G,
Wong J, Schiff R, Allred C, Clark G (2002) The estrogen receptor
coactivator AIB1 (SRC3) in combination with HER-2 is a prognostic and
predictive marker in patients with breast cancer. Proc Am Soc Clin Oncol
21: 33a (Abstract 129)
Pesenti E, Masferrer JL, di Salle E (2001) Effect of exemestane and celecoxib
alone or in combination on DMBA-induced mammary carcinoma in rats.
Breast Cancer Res 69: 288 (Abstract 445)
Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP,
Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su
LK, Sherman J, Kelloff G, Levin B, Steinbach G, FAP Study Group (2002)
A randomised, double blind, placebo controlled study of celecoxib, a
selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial
adenomatous polyposis. Gut 50: 857–860
Richards JA, Petrel TA, Brueggemeier RW (2002) Signalling pathways
regulating aromatase and cyclooxygenases in normal and malignant
breast cells. J Steroid Biochem Mol Biol 80: 203–212
Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C,
Joensuu H, Isola J (2002) Prognostic significance of elevated cyclo-
oxygenase-2 expression in breast cancer. Cancer Res 62: 632–635
Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura
S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2
in human colorectal cancer. Cancer Res 55: 3785–3789
Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M
(1999) Cyclooxygenase inhibitors suppress angiogenesis and reduce
tumor growth in vivo. Lab Invest 79: 1469–1477
Shishodia S, Koul D, Aggarwal BB (2004) Cyclooxygenase (COX)-2
inhibitor celecoxib abrogates TNF-induced NF-kappa B activation
through inhibition of activation of I kappa B alpha kinase and Akt in
human non-small cell lung carcinoma: correlation with suppression of
COX-2 synthesis. J Immunol 173: 2011–2022
Shou J, Massarweh S, Mohsin SK, Brown PH, Wakeling AE, Ali AS, Osborne
K, Schiff R (2002) Blockade of the estrogen receptor/growth factor cross-
talk implicated in breast cancer tamoxifen resistance using a selective
EGFR TK inhibitor. Program and Abstracts of the 25th San Antonio
Breast Cancer Symposium, December 11–14, 2002, San Antonio, Texas
(Abstract 246)
Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A,
Margreiter R, Obrist P (2003) Correlation of COX-2 and Ep-CAM
overexpression in human invasive breast cancer and its impact on
survival. Br J Cancer 88: 574–578
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB,
Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000)
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial
adenomatous polyposis. N Engl J Med 342: 1946–1952
Tan K-B, Yong W-P, Putti TC (2004) Cyclooxygenase-2 expression: a
potential prognostic and predictive marker for high-grade ductal
carcinoma in situ of the breast. Histopathology 44: 24–28
Tan P-H, Chuah K-L, Chiang G, Wong C-Y, Dong F, Bay B-H (2002)
Correlation of p53 and CerbB2 expression and hormonal receptor status
with clinicopathologic parameters in ductal carcinoma in situ of the
breast. Oncol Rep 9: 1081–1086
Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B,
Wissner A, Nunes M, Frost P, Discafani CM (2000) Combi-
natorial chemoprevention of intestinal neoplasia. Nat Med 6:
1024–1028
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998)
Cyclooxygenase regulates angiogenesis induced by colon cancer cells.
Cell 93: 705–716
Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow
RA, Masferrer JL, Woerner BM, Koki AT, Fahey III TJ (1999)
Cyclooxygenase-2 expression is up-regulated in human pancreatic
cancer. Cancer Res 59: 987–990
Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host
cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:
1511–1513
Woods JM, Mogollon A, Amin MA, Martinez RJ, Kock AE (2003) The role
of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 74:
282–290
Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen
biosynthesis proximal to a breast tumor is stimulated by PGE2 via
cyclic AMP, leading to activation of promoter II of the CYP19
(aromatase) gene. Endocrinology 137: 5739–5742
Potential of COX-2–aromatase inhibitor combinations
NJ Bundred and NLP Barnes
S15
British Journal of Cancer (2005) 93(Suppl 1), S10–S15 & 2005 Cancer Research UK